RxDoctor Payments Data

Tania Hudson, MD

Pulmonary Disease · Salisbury, MDNPI 1386634798

Payments from drug & device makers

$9,532in general payments, 2019–2025

Across 459 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Sanofi$682
  • Actelion Pharmaceuticals US, Inc.$600
  • Mallinckrodt Hospital Products Inc.$491
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,532 in reported general payments places this provider in the 70th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$172,942
Medicare patients
534
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter299$346,700
UptraviSelexipag11$257,877
OfevNintedanib Esylate19$255,580
Dupixent PenDupilumab29$129,423
Spiriva RespimatTiotropium Bromide55$67,010
Breo ElliptaFluticasone/Vilanterol72$65,848
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$51,874
Incruse ElliptaUmeclidinium Bromide38$28,890
Advair HfaFluticasone Propion/Salmeterol28$14,484
Combivent RespimatIpratropium/Albuterol Sulfate14$14,024
Arnuity ElliptaFluticasone Furoate27$12,973
Albuterol Sulfate HfaAlbuterol Sulfate176$9,815
Spiriva HandihalerTiotropium Bromide18$9,661
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$9,310
SymbicortBudesonide/Formoterol Fumarate23$5,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$1,211$454,411436 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$1,158$336,61488 claims
Actelion Pharmaceuticals US, Inc.Uptravi$600$257,87711 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,360$57,59761 claims
PfizerEliquis$47$4,87712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →